Abstract B005: Regulation of replication-induced PARP1/PARP2 activation by base excision repair: Implications for PARP and PARG inhibitor resistance

Abstract

Abstract Acquired poly (ADP-ribose) polymerases (PARP)-inhibitor (PARPi) and/or poly (ADP-ribose) glycohydrolase (PARG)-inhibitor (PARGi) resistance in BRCA1/2-defective tumors is common, emphasizing the need for identifying new targets. Protein poly ADP-ribosylation (PARylation) is a posttranslational modification of proteins catalyzed by PARP to form poly-(APD-ribose) (PAR) chains on itself and chromatin-associated proteins in response to DNA damage. Our study reveals that PARylation occurs in a replication-, PARP1-, and PARP2-dependent manner even in undamaged cells. Using proximity labeling, specifically Split-TurboID, we found that replication-dependent PARylation recruits the base excision repair (BER) factors XRCC1, POLB, APTX, and LIG3. These factors, in turn, suppress further PARylation. The BER factors XRCC1, POLB, APTX, or LIG3 promote PARPi and PARGi resistance as loss of these replication-associated BER (R-BER) factors re-sensitizes cancer cells to these inhibitors. Of interest, BRCA1 and BRCA2 localize with R-BER factors in undamaged cells. Lastly, XRCC1, POLB, APTX, and LIG3 depletion activate the S-phase checkpoint kinase CHK1, and targeting either this kinase or ATR under these conditions overcomes PARGi resistance in glioblastoma and ovarian cancer cells. In conclusion, our data highlight the crucial role of R-BER in protecting the cell during S-phase and propose a potential intervention strategy for resistant tumors. Citation Format: Md Ibrahim, Md Maruf Khan, Wynand P. Roos, Rasha Q. Al-Rahaleh, Faisal Hayat, Marie E. Migaud, Robert W. Sobol. Regulation of replication-induced PARP1/PARP2 activation by base excision repair: Implications for PARP and PARG inhibitor resistance [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B005.